JMP Securities Reiterates Market Outperform on Marinus Pharma, Maintains $10 Price Target
Portfolio Pulse from Benzinga Newsdesk
JMP Securities has reiterated its Market Outperform rating for Marinus Pharma, maintaining a $10 price target.
September 23, 2024 | 1:05 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
JMP Securities has reiterated its Market Outperform rating for Marinus Pharma, maintaining a $10 price target, indicating confidence in the company's future performance.
The reiteration of a Market Outperform rating and a maintained price target of $10 by JMP Securities suggests positive sentiment and confidence in Marinus Pharma's future performance. This could lead to a short-term positive impact on the stock price as investors may view this as a strong endorsement.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100